Test Interfering substance(s) Details of Assay Interference Source
AST Sulfasalazine/Sulfapyridine

Values may be  falsely reduced 

Roche Safety Notice  CCFSN_04-15 (2015)
ALT Sulfasalazine/Sulfapyridine Values may be  falsely reduced Roche Safety Notice  CCFSN_04-15 (2015)
BILT  IgG Interference ( ≥  28 g/L) Values may be  falsely elevated Roche Safety Notice CCFSN-BILT3,IGM-2,LACT2 SBM-CPS-2018-017 
Creatinine (Enzymatic)  N-Acetyl Cysteine (>333mg/L)

 

Dicynone (Ethamsylate)

 

Rifampicin

Levodopa Dexium

Methyldopa   (≥  20 mg/L)
Values may be  falsely reduced

Roche Safety Notice CCFSN-03-15 (2015)

HPRA SN2015(09) Issue Date: 21 05.15

Roche Safety Notice  CCA Endogenous Interferences QN-CPS-2018-113 15 JUL 2019)

CO2-L

IgG  ( ≥  35 g/L)

Not specified, results may be unreliable Roche Safety Notice  CCA Endogenous Interferences QN-CPS-2018-113 ( 2018)
CRP  IgG (≥  50 g/L) Not specified, results may be unreliable Roche Safety Notice  CCA Endogenous Interferences QN-CPS-2018-113 ( 15 JUL 2019)
Vitamin D Plasma Samples Values may be  falsely elevated EFSN ELECSYS VITAMIN D TOTAL II SBN-CPS-2018-005   (2018
Estradiol Fulvestrant Values may be  falsely elevated Method information sheet
Iron/TIBC/% Saturation Oxytetracycline,

Iron-Supplements,

Desferoxamine

Ferritin (>1200ug/L)
Not specified, results may be unreliable Method information sheet
Lipids (Chol, Trig, HDL, LDL) N-Acetyl Cysteine Values may be  falsely reduced

Roche Safety Notice CCFSN-03-15

HPRA SN2015

Testosterone Nandrolone Not specified, results may be unreliable Method information sheet
Uric Acid N-Acetyl Cysteine Values may be  falsely reduced Roche Safety Notice CCFSN-03-15 May (2015) HPRA SN 2015(09) 
Immunoassays - Cobas 6000

TESTS INCLUDE

Anti-HBS

HBsAg II

HCV

HBC

SPYH

Rubella

HIV

TNT hs

VIT D

AMHP

VIT B12

βeta-HCG ESTRADIOL FERRITIN FOLATE

FSH

FREE T3

FREE T4

T4

LH

PRL

PRG

TESTO

TSH

TPSA  
Biotin > 5mg/day  

Not specified, results may be unreliable.

Samples should not be taken until at least 8 hours following biotin administration.

 

Method information sheet,

SN-CPS-2019-034 (21 Jun 2019)

SN-CPS-2019-031( 25 APR 2019)

SBN-CPS-2018-016 (18 SEP 2018)

THIS IS NOT A COMPLETE LIST. PLEASE CONTACT THE LABORATORY IF YOU REQUIRE FURTHER INFORMATION.

IF RESULTS ARE NOT CONSISTENT WITH CLINCAL FINDINGS, PLEASE CONTACT US AND WE WILL, WHERE POSSIBLE, ARRANGE FURTHER TESTING USING A DIFFERENT PLATFORM.

 

INTERFERENCE LIST CLINICAL CHEMISTRY AUTOLAB MEDLAB PATHOLOGY v1 July 2019